The National Alliance on Mental Illness (NAMI), a United States-based grassroots mental health organisation, announced on Friday that its CEO, Daniel H Gillison, Jr, has been recognised with the 2025 Not Alone Pioneer Award by the Inspiring Children Foundation.
The award was conferred at the Not Alone Awards during the inaugural Not Alone Summit.
Gillison has been recognised as a trailblazer who is 'redefining what's possible in mental health research, advocacy, and healing.'
Gillison said: "I'm deeply honoured by this recognition, because it reflects who NAMI is -- a community built on compassion, connection, and care. For nearly 50 years, we've helped people see that they're not alone, and that together, healing and hope are possible. I'm grateful to the Inspiring Children Foundation and the Not Alone Summit for amplifying the importance of coming together around mental health and hope."
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA